Europe
OptiBiotix Health has named Adam Reynolds as Non-Executive Chairman of its new specialist probiotic subsidiary ProBiotix Health Limited. With 14 commercial deals in just under 18 months and a strong deal pipeline in place ProBiotix is well placed to become a stand-alone company.
CPhI Worldwide pharma survey shows improving outlook for pharma economies globally, with China and India showing the fastest improvement
VTU Technology GmbH announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
-- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model --
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
As we end October and head into November, the Food and Drug Administration (FDA) continues its work. This upcoming week has several PDUFA action dates for drug applications. Here’s a look.
Lundbeck Schizophrenia Drug Fails to Differentiate Itself from Conventional Therapies, Stocks Plunge
Shares of H. Lundbeck A/S plunged more than 25 percent after the company announced Thursday that its Phase III treatment for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies.
Agreement demonstrates growing use of OncoDNA solutions across Europe
MEDICAL professionals are being offered the chance to improve patient safety thanks to a series of webinars delivered by biomedical testing experts at Rigel Medical.
Polyganics today announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL®, its dura sealant patch. The self-adhesive patch has been developed to reduce cerebrospinal fluid (CSF) leakage following brain surgery.
PRESS RELEASES